Palisade Bio, Inc. (PALI)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Operating profit | $m | -18 | -35 | ||||||
| Net profit | $m | -10 | -27 | -14 | -12 | -14 | -17 | -32 | -12 |
| EPS reported | $ | -0.30 | -0.53 | ||||||
| Operating cashflow per share | $ | -0.19 | -0.09 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.19 | -0.09 | ||||||
| Free cash flow | $m | -11 | -18 | ||||||
| Net debt | $m | -133 | -125 | ||||||
| Book value equity | $m | 129 | 122 | ||||||
| Book value per share | $ | 2.32 | 0.58 | ||||||
| Number of shares | m | 55.67 | 211.38 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.01 | 1.07 | ||||||
| P/S LTM | x | 0.00 | 261.65 | ||||||
| P/FCF LTM | x | -12.06 | -7.19 | ||||||
| EV/EBITDA LTM | x | 0.15 | 0.07 | ||||||
| EV/Sales LTM | x | 0.00 | 492.58 | ||||||
| Earnings Yield LTM | % | -12.83% | -7.06% | ||||||
| FCF Yield | % | -8.29% | -13.90% | ||||||
| Quality | |||||||||
| ROE | % | -12.97% | -33.47% | ||||||
| ROIC | % | -13.91% | -28.96% | ||||||
| Operating margin | % | 0.00% | -70.70% | ||||||
| Gross margin | % | 0.00% | +100.00% | ||||||
| FCF/Sales | % | - | -3638.0% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -152.77 | - | ||||||
| Net Debt/EBITDA | x | 7.95 | 3.77 | ||||||
| EBIT/Net interest | x | -1,805.60 | -5,891.50 | ||||||
| Net debt/market cap | % | +0.05% | 0.00% | ||||||
| Net debt/Equity | x | -1.03 | -1.03 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free